NovoCure Limited - Ordinary Shares (NVCR): Price and Financial Metrics

NovoCure Limited - Ordinary Shares (NVCR)

Today's Latest Price: $115.89 USD

3.61 (-3.02%)

Updated Oct 28 9:57am

Add NVCR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NVCR Stock Summary

  • With a price/earnings ratio of 1,041.16, NovoCure Ltd P/E ratio is greater than that of about 99.16% of stocks in our set with positive earnings.
  • Price to trailing twelve month operating cash flow for NVCR is currently 335.89, higher than 98.95% of US stocks with positive operating cash flow.
  • NVCR's price/sales ratio is 30.03; that's higher than the P/S ratio of 94.09% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to NovoCure Ltd are FLGT, QLYS, SEDG, MOMO, and RNG.
  • To check out NovoCure Ltd's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001645113.

NVCR Stock Price Chart Interactive Chart >

Price chart for NVCR

NVCR Price/Volume Stats

Current price $115.89 52-week high $140.89
Prev. close $119.50 52-week low $53.40
Day low $114.28 Volume 114,000
Day high $118.04 Avg. volume 996,970
50-day MA $106.26 Dividend yield N/A
200-day MA $79.89 Market Cap 11.72B

NovoCure Limited - Ordinary Shares (NVCR) Company Bio

NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.

NVCR Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$115.89$1259.21 936%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for NovoCure Ltd. To summarize, we found that NovoCure Ltd ranked in the 85th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 941.5%. In terms of the factors that were most noteworthy in this DCF analysis for NVCR, they are:

  • The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than merely 6.15% of the free cash flow producing stocks we're observing.
  • As a business, NovoCure Ltd experienced a tax rate of about 211% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 98.16% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as NVCR, try ARGX, HCA, NHC, FVE, and VMD.

NVCR Latest News Stream

Event/Time News Detail
Loading, please wait...

NVCR Latest Social Stream

Loading social stream, please wait...

View Full NVCR Social Stream

Latest NVCR News From Around the Web

Below are the latest news stories about NovoCure Ltd that investors may wish to consider to help them evaluate NVCR as an investment opportunity.

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...

Benzinga | September 17, 2020

Top Analyst Upgrades and Downgrades: Boston Scientific, CVS, FMC, Lennar, NovoCure, Penn National, Ruth’s, Stitch Fix, Veeco and More

No summary available.

24/7 Wall street | September 17, 2020

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...

Benzinga | September 16, 2020

NovoCure (NVCR): Why this medtech firm matters

Even as COVID-19 is wreaking havoc across the world, cancer continues to kill about 10 million people per year, and the quest for the most effective cure is gaining pace. In fact, the coronavirus pandemic has reportedly accelerated the cancer fatality rate, further stressing the urgent need to scale up oncology research. Thanks to the […]

AlphaStreet | September 14, 2020

Novocure Announces Expansion of Its Executive Leadership Team

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020.

Business Wire | August 13, 2020

Read More 'NVCR' Stories Here

NVCR Price Returns

1-mo 6.99%
3-mo 52.15%
6-mo 91.62%
1-year 60.58%
3-year 495.84%
5-year 415.75%
YTD 37.52%
2019 151.70%
2018 65.74%
2017 157.32%
2016 -64.89%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7141 seconds.